肿瘤药学Issue(6)：447-450,4.DOI:10.3969/j.issn.2095-1264.2013.109
回生口服液对晚期非小细胞肺癌患者血清IL-6和IL-18的影响
Effects of Hui-sheng Oral Liquid on the Expression of Interleukin-6 and Interleukin-18 of Patients with Advanced Non-small-cell Lung Cancer
贾友超 1魏亚宁 1申红强 2田彦敏 3臧爱民1
作者信息
- 1. 河北大学附属医院肿瘤内科，河北 保定，071000
- 2. 保定市清苑县人民医院 2放射科
- 3. 超声科，河北 保定，071100
- 折叠
摘要
Abstract
Objective To detect the effects of Hui-sheng oral liquid on the expression of Interleukin-6 and Interleukin-18 of patients with advanced non-small-cell lung cancer (NSCLC) and to investigate its possible anti-tumor mechanism. Methods Eighty-two patients with advanced NSCLC were recruited and randomly divided into two groups:the combined chemotherapy group (NP chemotherapy and hui-sheng oral liquid, n=42) and the single chemotherapy (only NP chemotherapy, n=40). The ef-fective rates were evaluated after two cycles’treatment. The expression of serum IL-6 and IL-18 were detected by the enzyme linked immunoassay (ELISA) before and after two cycles’treatment. Results The total effective rate was 38.1%(16/42) for the combined chemotherapy group, and 35.0%(14/40) for the single chemotherapy group;there was no significant difference (P=0.697) between the two groups. No difference was found in the expression of IL-6 and IL-18 before and after treatment in the single chemotherapy group (P=0.623). While compared with before treatment, the expression of both IL-6 and IL-18 were significantly up-regulated after treatment in combined chemotherapy group (P=0.005). Conclusion The adjuvant treatment with Hui-sheng oral liquid could increase the expression of IL-6 and IL-18 of patients with NSCLC and enhance their immunizing power.关键词
回生口服液/IL-6/IL-18/非小细胞肺癌Key words
Hui-sheng oral liquid/IL-6/IL-18/Non-small-cell lung cancer分类
医药卫生引用本文复制引用
贾友超,魏亚宁,申红强,田彦敏,臧爱民..回生口服液对晚期非小细胞肺癌患者血清IL-6和IL-18的影响[J].肿瘤药学,2013,(6):447-450,4.
